Dogwood Therapeutics, Inc.

For the period ended May 14, 2026. Filed May 14, 2026.

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

May 14, 2026 · Filed May 14, 2026

Use the contents to explore the available documents and sections.

DWTX$1.28+23.1%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

EX-99.1 · Selected Financial Data

Selected Financial Data

(unaudited)

Condensed ConsolidatedStatements of Operations Data · · · Three Months EndedMarch 31, ·
	2026	2025
Revenue	$—	$—
Operating expenses:
Research and development	2,669,779	2,436,998
General and administrative	2,406,587	1,992,928
Total operating expenses	5,076,366	4,429,926
Loss from operations	(5,076,366)	(4,429,926)
Other income (expense):
Sublease income	19,455	—
Loss on debt conversion with related party	—	(6,134,120)
Interest income (expense), net	77,350	(147,090)
Exchange loss, net	(5,860)	(23,274)
Total other income (expense), net	90,945	(6,304,484)
Loss before income taxes	(4,985,421)	(10,734,410)
Deferred income tax expense	(1,193)	(190,542)
Net Loss	(4,986,614)	(10,924,952)
Accrual of paid-in-kind dividends on Series A non-voting convertible preferred stock	—	(1,256,662)
Net loss attributable to common stockholders	$(4,986,614)	$(12,181,614)
Net loss per share of common stock — basic and diluted	$(0.15)	$(8.45)
Weighted average shares outstanding — basic and diluted	33,544,748	1,441,535

Condensed Consolidated Balance Sheet Data · March 31, · · · December 31, ·
· 2026 · · · 2025 ·

Cash and cash equivalents	$13,227,839	$6,524,744
Total assets	95,207,871	90,171,237
Total liabilities	14,584,519	15,274,370
Total stockholders’ equity	80,623,352	74,896,867

Source: Dogwood Therapeutics, Inc.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.